Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmari

Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting

Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting

itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Texas , United States , California , San Diego Convention Center , Jukka , Lapland , Finland , San Diego , Helsinki , Eteläuomen Läi , Boston , Massachusetts , American , Jo Turner , Mary Jane Elliott , Sandy Jamieson , Lindsey Neville , Mika Kontro , Juha Karttunen , Christopher Golden , David Daley , Peel Hunt , Cairn Financial Advisers , American Society Of Hematology , University Of Texas Md Anderson Cancer Center , Faron Pharmaceuticals Ltd , Faron Pharmaceuticals , First North , American Society , Efficacy Observed , Assess Safety , Myeloid Leukemias , Investigational Therapies , Excluding Transplantation , Diego Convention Center , Associate Professor , Naval Daver , Jane Elliott , Certified Adviser , Nasdaq First ,